News

Changes in the gene activity within immune T-cells explain why women with multiple sclerosis (MS) improve during pregnancy, a study reports. Gene activity changes during and after pregnancy were highly similar between MS patients and healthy women. Many of the genes whose activity was altered during pregnancy were associated…

Altered blood levels of certain fat molecules implicated in inflammatory responses seem to correlate with disability status and markers of nerve damage in people with multiple sclerosis (MS), particularly in those with progressive forms of the disorder, a study reported. Findings highlight the potential role of these fat, or…

A microRNA called miR-548a-3p, a small molecule important for regulation of gene activity, may help to identify people with multiple sclerosis (MS) who will reach no evidence of disease activity — a status known as NEDA-3 — after treatment with Gilenya (fingolimod), a study found. Data showed that…

The over-the-counter antihistamine clemastine has demonstrated an ability to repair myelin, the protective coating on nerve fibers that’s damaged in multiple sclerosis (MS), according to an analysis of MRI data from the ReBUILD clinical trial. The changes in myelin were examined with a noninvasive MRI method that more…

To address knowledge gaps and avoid duplicate efforts in the lab and in trials, 10 multiple sclerosis (MS) organizations from around the world have committed to a single global research strategy to find a cure for the progressive neurodegenerative disorder. The nonprofits, with headquarters in countries ranging from the…

Alterations in the levels of certain fat molecules in the bloodstream are significantly associated with a higher risk of relapse and a poorer disability status in children and adolescents with multiple sclerosis (MS), according to a recent study. It’s not yet clear if such alterations contribute to the inflammation…

Aneuro, a brand of the biotechnology company ACROBiosystems, is partnering with the biosensor maker Diagnostic Biochips to help bring to market new approaches to treating disorders such as multiple sclerosis (MS). Specifically, the companies are collaborating to launch electrophysiology solutions that can be used in living…

A blood-clotting protein called fibrin can activate immune cells in the brain and contribute to inflammation and neurodegeneration in multiple sclerosis (MS), a study revealed. Because blood vessels become leaky in neurodegenerative conditions like MS, the blood can cross into the brain, which is known to activate multiple pro-inflammatory…

Ocrevus (ocrelizumab) appears to be more effective than rituximab at reducing relapse activity in people with relapsing-remitting multiple sclerosis (RRMS), but disability progression outcomes are comparable between the therapies, an observational study of patients reported. “Study findings suggest that the effectiveness of rituximab on MS relapses was…

It’s been three decades since the first treatment for multiple sclerosis (MS) was approved. In that time, the field has made substantial advances — including the approval of over two dozen medications — but there’s still a long way to go to improve care for progressive forms of…

The protein DDX39B is a master regulator of immune tolerance, or the immune system’s ability to distinguish self from potentially harmful nonself molecules, and helps to control the development of immune cells that are key for this process, a new study shows. Findings suggest that activating DDX39B with small molecules…

Engaging in physical activity may improve the quality of life for people newly diagnosed with multiple sclerosis, a link that remained even after accounting for other factors such as fatigue and disability status, a study shows.

Pipeline Therapeutics will soon launch a Phase 1 clinical study to test PIPE-791, one of its candidate treatments for multiple sclerosis (MS), in healthy volunteers. The announcement follows a go-ahead from the U.S. Food and Drug Administration (FDA) for an investigational new drug (IND) application to initiate clinical…

Ocrevus (ocrelizumab) — given by infusion — may work better than certain oral treatments to prevent relapses and disability worsening in people with relapsing-remitting multiple sclerosis (RRMS) who transition from Tysabri (natalizumab), a new study found. Individuals who switched to Ocrevus also were more likely to stay…

The National Multiple Sclerosis Society (NMSS) has earned a shoutout from the digital fundraising platform DonorDrive for being recognized as one of the top 30 peer-to-peer fundraising programs in the U.S. by the Peer-to-Peer Professional Forum. MS Canada also made the list for the top…

Reductions in microglial activation have been observed in the brains of five of six patients with nonactive secondary progressive multiple sclerosis (SPMS) who received treatment with Tiziana Life Science’s foralumab nasal spray. Microglia, resident immune cells in the brain, are believed to play a role in driving inflammation…

For people with multiple sclerosis (MS), all forms of exercise are likely to be beneficial for physical fitness, but certain forms of exercise may be better than others at improving specific measures of fitness, according to a review of multiple clinical trials. Results suggest that resistance training — pushing…

Disease-associated inflammatory activity of microglia — a type of immune cell with a central role in the development of multiple sclerosis (MS) — is driven in part by molecular mechanisms that are activated when microglia try to clear the corpses of dead myelin-making cells. That’s according to a new…

People with relapsing multiple sclerosis (MS) who experienced disease activity while on oral therapies had less disease activity after switching to Kesimpta (ofatumumab), according to an analysis of data from the Phase 3 ARTIOS clinical trial. The patients previously were on Gilenya (fingolimod), or fumarate-based therapies such…

Microparticles that activate regulatory T-cells, or Tregs, an immune cell type with anti-inflammatory properties, reversed the accumulation of physical disability due to multiple sclerosis (MS) in a mouse model of the neurodegenerative disorder, a new study shows. Use of the novel strategy even cured some of the animals. “We…

Physical disability, not whether patients are depressed, when they’re diagnosed with multiple sclerosis significantly influences their future disability progression, according to a recent U.K. registry study. Although patients who were depressed at the time of their diagnosis were more likely to accumulate significant disability and require an aid to…

Analyses of protein levels in the blood can be used to identify groups of multiple sclerosis (MS) patients with distinct clinical features, new research shows. Given the variability of symptoms among people with MS, such groupings could help to improve individualized care for patients, according to Octave, a…

As part of last week’s World MS Day, a documentary about the life of Mathew Embry, a multiple sclerosis (MS) patient who’s been living symptom-free for more than 27 years, has premiered on national Canadian television. The critically acclaimed documentary, called “Living Proof,” premiered June 4 on The…

Long-term treatment with vidofludimus calcium (IMU-838) has been tolerated well overall among people with relapsing-remitting MS (RRMS), new data from an extension study show. Findings were presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, in a poster titled “Assessment of Long-Term Safety…

The European Commission has approved Briumvi (ublituximab) for the treatment of adults with relapsing forms of multiple sclerosis (MS) who have active disease, as defined by clinical or imaging features. The approval, which covers all member states in the European Union, as well as Iceland, Norway, and Liechtenstein,…

Being exposed to stress as children or adults makes it more likely that people with multiple sclerosis (MS) will experience more disability and/or a heavier burden from relapses, according to a new survey study of more than 700 people in the U.S. “MS is the leading cause of non-traumatic…

Frexalimab, an experimental anti-CD40L antibody therapy from Sanofi, significantly reduced the number of new brain lesions with active inflammation in people with relapsing forms of multiple sclerosis (MS), according to new Phase 2 clinical trial data. Sanofi believes its second-generation CD40L blocker will effectively control immune activity in…

A detailed examination of nerve tissue isolated from multiple sclerosis (MS) patients showed changes to the myelin sheath before the appearance of substantial inflammatory activity and lesions, a study reported. In MS patients, normal-appearing brain regions showed a less compact, detached, and disorganized myelin composition that may make…

In an effort to improve access to medical care for all people with multiple sclerosis (MS), the Consortium of Multiple Sclerosis Centers (CMSC) has announced new initiatives to address disparities and inequality in MS care. The consortium is incorporating a new statement on Diversity, Equity, and Inclusion (DEI)…

More treatment centers for people with autoimmune disorders such as multiple sclerosis (MS) are now available in Florida, as IVX Health expands its footprint across the state with the addition of two outpatient infusion and injection centers in the Fort Lauderdale area. With the new locations in Pembroke…